Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Receivables: 2015-2023

Historic Change in Receivables for Spyre Therapeutics (SYRE) over the last 6 years, with Dec 2023 value amounting to -$163,000.

  • Spyre Therapeutics' Change in Receivables rose 44.56% to -$163,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$375,000, marking a year-over-year increase of 14.77%. This contributed to the annual value of -$375,000 for FY2023, which is 14.77% up from last year.
  • Per Spyre Therapeutics' latest filing, its Change in Receivables stood at -$163,000 for Q4 2023, which was up 89.01% from -$1.5 million recorded in Q3 2023.
  • In the past 5 years, Spyre Therapeutics' Change in Receivables registered a high of $21.5 million during Q1 2021, and its lowest value of -$21.5 million during Q2 2021.
  • In the last 3 years, Spyre Therapeutics' Change in Receivables had a median value of -$45,000 in 2023 and averaged $0.
  • The largest annual percentage gain for Spyre Therapeutics' Change in Receivables in the last 5 years was 346.90% (2023), contrasted with its biggest fall of 880.53% (2023).
  • Over the past 3 years, Spyre Therapeutics' Change in Receivables (Quarterly) stood at $815,000 in 2021, then plummeted by 136.07% to -$294,000 in 2022, then spiked by 44.56% to -$163,000 in 2023.
  • Its Change in Receivables stands at -$163,000 for Q4 2023, versus -$1.5 million for Q3 2023 and $1.3 million for Q2 2023.